- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01006018
DPP-4 Inhibition and TZD for DM Prevention (DInT DM)
November 12, 2013 updated by: Dr. Mary Rhee, Emory University
DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Impaired glucose tolerance (IGT) by oral glucose tolerance test
Exclusion Criteria:
- History of diabetes mellitus
- History of congestive heart failure
- History of coronary artery disease or other macrovascular disease (stroke, peripheral vascular disease)
- History of liver disease (ALT or AST >2.5 times the upper limit of normals)
- History of renal disease (serum creatinine >1.5 mg/dl)
- History of severe osteoporosis (frequent fractures, failure on osteoporosis treatment)
- Current treatment with glucocorticoids
- History of immune disorder, including HIV
- Women of child-bearing age who are pregnant, desire to become pregnant, are breastfeeding, or who refuse to take the recommended birth control measures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sitagliptin + Pioglitazone PLACEBO
Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth + pioglitazone PLACEBO daily by mouth |
Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
Other Names:
|
Experimental: Sitagliptin + Pioglitazone
Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth + pioglitazone (TZD) 15 mg daily by mouth |
Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
Other Names:
|
Placebo Comparator: PLACEBO
Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth + pioglitazone (TZD) PLACEBO daily by mouth |
Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin Secretion
Time Frame: baseline, 6 months, 9 months (after a 3 month washout)
|
Not measured as study was prematurely terminated due to unanticipated delays.
|
baseline, 6 months, 9 months (after a 3 month washout)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mary Rhee, MD, Emory University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
October 27, 2009
First Submitted That Met QC Criteria
October 30, 2009
First Posted (Estimate)
November 1, 2009
Study Record Updates
Last Update Posted (Estimate)
December 5, 2013
Last Update Submitted That Met QC Criteria
November 12, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Prediabetic State
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Pioglitazone
- Sitagliptin Phosphate
Other Study ID Numbers
- IRB00015390
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prediabetic State
-
Aga Khan UniversityUniversity of Helsinki; International Diabetes FederationUnknownPrediabetic State & High Risk IndividualsPakistan
-
Ingredia S.A.BioTeSys GmbHCompletedPrediabetic StateGermany
-
Dexa Medica GroupCompleted
-
Gadjah Mada UniversityUniversitas Islam IndonesiaRecruitingPreDiabetes | Prediabetic StateIndonesia
-
Riphah International UniversityCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
National Research Council, SpainCompleted
-
InLight SolutionsCompletedHealthy | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Prediabetic State (IGT)United States
-
Centro Universitario de Ciencias de la Salud, MexicoRecruiting
-
Shri Ramachandra Bhanj Medical CollegeCompleted
Clinical Trials on Sitagliptin + Pioglitazone PLACEBO
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus (T2DM)
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCCompleted
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus